Journal article icon

Journal article

Anti-TNFalpha therapy for rheumatoid arthritis: an update.

Abstract:

Many studies have confirmed that the long term use of biological agents targeting TNFalpha in therapy for rheumatoid arthritis give rise to sustained improvement in symptoms and signs of disease provided the anti-TNF agent is efficacious and of low immunogenicity. The current regimes for infliximab 3 or 10 mg/kg infusion in combination with weekly oral methotrexate, or of subcutaneous etanercept 25 mg twice per week fulfil these criteria. D2E7, a 'human' antibody produced by phage display, ha...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, NDORMS
Journal:
Internal medicine (Tokyo, Japan)
Volume:
42
Issue:
1
Pages:
15-20
Publication date:
2003-01-05
DOI:
EISSN:
1349-7235
ISSN:
0918-2918
URN:
uuid:d17dee68-5a99-4945-ab96-d11f70432c34
Source identifiers:
226784
Local pid:
pubs:226784

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP